©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Hepatocellular carcinoma: From diagnosis to treatment
Abhijeet Waghray, Department of Medicine, MetroHealth Medical Center/Case Western Reserve University, Cleveland, OH 44109, United States
Arvind R Murali, Department of Gastroenterology and Hepatology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, United States
KV Narayanan Menon, Department of Gastroenterology and Hepatology, Digestive Disease Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, United States
Author contributions: All authors contributed to this manuscript.
Conflict-of-interest: The authors have no financial or grant support conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Abhijeet Waghray, MD, Department of Medicine, MetroHealth Medical Center/Case Western Reserve University, 2500 MetroHealth Drive, Cleveland, OH 44109, United States. firstname.lastname@example.org
Received: September 5, 2014
Peer-review started: September 5, 2014
First decision: November 27, 2014
Revised: January 15, 2015
Accepted: February 10, 2015
Article in press: February 12, 2015
Published online: May 18, 2015
Hepatocellular carcinoma (HCC) is the sixth most common malignancy and is the leading cause of mortality in patients with cirrhosis. An estimated half million new cases are diagnosed each year world-wide with disease burden highest in developing countries (85% of all cases)[2,3]. The average age of diagnosis is 65 years with a shift in the last decade toward diagnosis at an earlier age. This trend is especially seen in developing countries and has implications for treatment. Rates of HCC are two to four times higher in men compared to women. Over the past 20 years there has been a 3 fold increase in the number of new HCC cases in the United States (estimated 33190 in 2014)[2,6,7]. The rising incidence of HCC in Western countries appears to correlate with the increasing prevalence of hepatitis C virus (HCV). Currently, the incidence of HCC continues to rise and the 5 year survival rate remains low. Monotherapy agents targeting HCV have made curative therapy in chronic infection possible and may eventually translate into lower rates of HCC. One may presume that despite the high cost of the monotherapy agents, there will be a profound impact on the downstream costs and related complications from chronic HCV and HCC.
Risk factors for HCC are well documented and effective surveillance with early diagnosis allows for curative measures.
Cirrhosis is the most important risk factor for developing HCC and is present in 80% to 90% of individuals. The annual incidence of liver cancer in patients with cirrhosis is 1% to 6 %. Although there exists wide regional variations in distribution and etiology of HCC, chronic hepatitis B virus (HBV) and HCV infection represent the majority of HCC cases worldwide. The highest incidence of HBV is in eastern Asia and sub-Saharan Africa where it accounts for the majority of cases (greater than 50%). Viral load, duration of infection and rate of replication are related to the incidence of HCC[11,12]. Further, a risk association between HBV and HCC is present in endemic areas where the pattern of transmission is from mother to newborn. Several mechanisms for HBV progression to HCC are proposed. Viral integration into liver cells may cause chromosomal instability and alteration of normal cellular replication resulting in HCC[13,14]. Further, inflammatory and/or necrotic changes from HBV may alter hepatocyte genetic expression or directly induce malignancy.
On the other hand, HCC cases in North America, Europe and Japan are highest among HCV infected patients. Annual incidence of HCC is 1% to 4% in patients with HCV related cirrhosis[16,17]. Compared to HCV negative patients, individuals with chronic HCV infection have a 17 times higher risk of developing HCC. In the United States, it is estimated that the incidence of HCV will continue to rise in the following decades[18,19]. It is hypothesized that the primary mechanism for HCC in HCV patients is inflammatory hepatocyte damage from oxidative stress, promoting cirrhosis.
Alcohol related liver disease and non-alcoholic fatty liver disease increase the risk of HCC alone or in combination with HBV/HCV. Further, obesity and diabetes are independent risk factors for the development of HCC[21-23]. In patients with chronic viral hepatitis, obesity may synergistically increase the risk of HCC by 100 fold. It has also been elicited that patients with a higher BMI often have a higher rate of mortality. In addition, the number of metabolic syndrome components in a given patient appears to correlate with an increased risk of HCC. As rates of patients diagnosed with metabolic syndrome rise around the world, even a small contribution to the development of HCC would have a devastating impact.
Finally, a number of less common risk factors for HCC include hereditary hemochromatosis, autoimmune hepatitis, glycogen storage diseases, primary biliary cirrhosis, alpha1-antitrypsin deficiency, and Wilson’s disease.
Studies for preventive strategies have centered on viral causes of HCC and minimal data exists on risk reduction for other etiologies. Although vaccination and anti-viral treatment remain the primary means of prevention, counseling patients on dietary modifications, weight loss and tobacco/alcohol cessation remain important steps to address.
The HBV vaccine is effective at preventing HCC and vaccination programs have lowered rates of related malignancy. Over a 10-year period, the Taiwan universal vaccination program reduced the annual incidence of HCC from 0.70 to 0.36 per 100000 children. Thus, one would suspect that initiation of universal vaccination programs in children would have an overall reduction in HCC disease burden in adults. For adults with chronic HBV infection, vaccinations have no role in preventing HCC. Rather, one must focus on anti-viral treatment. Treatment with interferon alpha (IFN-α) reduced the risk of HCC by 6.4% in a meta-analysis of seven studies. Further analysis revealed that the protective effects of IFN-α were limited to patients with cirrhosis. Other treatment options include nucleoside/nucleotide analog treatments and most published data is on lamivudine or adefovir. Treatment with these agents appear to effectively suppress viral replication and decrease the risk of developing HCC[30-32].
Antiviral treatment for HCV may also reduce the risk of HCC. In several studies, treatment by IFN with sustained viral response correlated with a decreased risk of HCC compared to non-responders or no treatment[33,34]. Newer treatment options for HCV with improved viral response rates may effectively reduce progression to HCC.
Practice guidelines recommend standardized surveillance programs for HCC with decision analysis models showing that surveillance improves survival and is cost effective if the annual rate of HCC exceeds 1.5% in a given population[35,36]. Diagnosis at an early stage of HCC confers a survival benefit compared to patients diagnosed with advanced disease. Curative treatment options such as liver transplantation available in early stage disease likely contribute to this survival benefit.
Hepatic ultrasound and alpha-fetoprotein (AFP) have historically played a prominent role in HCC surveillance. A randomized controlled trial of 18861 participants assessed the effect of screening on HCC mortality. All study participants had HBV and were divided into 2 groups: patients who underwent screening with ultrasound every 6 mo and AFP compared with no surveillance. Surveillance was associated with a 37% reduction in HCC mortality, despite sub-optimal adherence to surveillance (< 60%).
For over 40 years AFP has been used in the detection of HCC with variable sensitivity (39% to 65%), specificity (76% to 94%) and positive predictive value (9% to 50%)[39-43]. Results from several studies have challenged the utility of AFP in screening. A randomized controlled trial of 5581 HBV patients showed that AFP bi-annual screening improved detection rates of HCC but earlier detection did not translate to decreased mortality. Concurrent AFP and ultrasound testing increased false positive rates and led to unnecessary diagnostic testing. Further, data suggest that for lesions less than 2 cm in diameter, AFP will rarely be elevated[41,45,46]. An inherent disadvantage of AFP is that it can be elevated in chronic hepatitis even without HCC, resulting in low specificity. Current AASLD guidelines do not recommend AFP for screening or diagnostic purposes. Research into novel biomarkers for early HCC detection continue. As more sensitive assays such as AFP-L3 are developed, the role of serology for surveillance maybe re-analyzed.
The ideal modality for HCC screening remains an area of controversy. Although the recommended method of surveillance is liver ultrasonography, diagnosis by this modality remains operator and equipment dependent (sensitivity of 65% and specificity of 90%). Older studies have shown ultrasonography to be equivalent to computed tomography (CT) in detecting hepatic lesions[48,49]. But more recently, research into CT and magnetic resonance imaging (MRI) for HCC screening have yielded promising results in lesions greater than 2 cm. Prospective trials are needed before CT or MRI can replace ultrasonography as the primary screening method for HCC. Specifically cost effectiveness, cumulative radiation exposure and mortality benefit will need to be addressed.
The 6 mo interval length for screening is based on tumor doubling time and is not dictated by risk factors for HCC. A shorter 3 mo interval increased small nodule detection without affecting survival rates, while longer periods between screening (12 mo) showed an increased rate of advanced tumors. Once a lesion has been detected, the size of the lesion determines the next step. Hepatic nodules less than 1 cm should be followed with repeat ultrasonography every 3 mo. If the lesion is stable over 2 years then a return to routine 6 mo surveillance is acceptable. Liver lesions exceeding 1 cm warrant further evaluation as described below.
Definitive diagnosis via non-invasive testing includes four-phase multidetector CT (unenhanced, arterial, venous and delayed) or dynamic contrast enhanced MRI. The presence of arterial hyper-enhancement with a venous or delayed phase washout of contrast medium, confirms a diagnosis of HCC. While MRI provides superior contrast resolution compared to CT, metallic implants, respiratory artifact, significant ascites, cost and availability all limit its use. Patients with atypical features for HCC either on CT or MRI should undergo the other imaging modality or lesion biopsy. Individuals with discordant CT/MRI findings or hepatic lesions without cirrhosis should also receive a liver biopsy. The imaging modalities above are valid for patients with cirrhosis or chronic HBV without cirrhosis. Contrast enhanced ultrasonography should not be used for diagnostic purposes as it lacks specificity for HCC. Unfortunately, biopsies also carry a high false negative rate (up to 30%) - attributed to inadequate sampling. Despite a negative biopsy, surveillance of the lesion at 3 to 6 mo intervals for changes characteristic for HCC or for lesion enlargement should be completed. Lesions less than 1 cm are difficult to assess even with the combination of imaging and biopsy (Figure 1).
Figure 1 Diagnostic algorithm for hepatocellular carcinoma.
Reproduced from Bruix J. Hepatology. 2011. CT: Computed tomography; MRI: Magnetic resonance imaging; HCC: Hepatocellular carcinoma.
Several treatment options exist for patients with HCC and can be categorized as curative or palliative. The three potentially curative options are radiofrequency ablation, liver transplantation, or tumor resection. Given the heterogeneity of HCC and complexity of treatment options patients are optimally managed by a multi-disciplinary team. The best therapy is determined based on the stage of presentation. The barcelona clinic liver cancer staging system, developed in 1999, is a common means to assess prognosis and select appropriate therapy for HCC. In general, surgical resection or liver transplantation is the first line treatment option for early stage HCC; whereas asymptomatic patients with intermediate stage disease benefit from chemoembolization. Patients with end stage HCC or extensive extrahepatic disease often have a less than 3 mo rate of survival. In these individuals, pain and symptom control to improve quality of life should be the primary focus.
Other staging systems such as Cancer of Liver Italian Program, Okuda stage, French staging system have been validated to a lesser extent. Biomarkers such as vascular endothelial growth factors may have prognostic value in the future.
Surgical resection is the therapy of choice in early stage HCC without cirrhosis or in the absence of portal hypertension. Selection criteria have been refined over the years and include individuals with a tumor size less than 3 cm in diameter, normal bilirubin and absence of portal hypertension. In patients without cirrhosis, a 60% to 75% five year survival rate can be achieved[57,58]. Hepatic function evaluated by Model for End Stage Liver Disease (MELD) or Child-Pugh correlate with survival following resection. As expected, patients in Child-Pugh A classification have an improved survival rate following resection compared with those in class B or C[59,60]. In the United States only 5% of individuals will qualify for resection, while in Asia younger age of presentation allows 40% of patients to qualify for surgical resection. Laproscopic liver resection accounts for 10%-20% of procedures in the United States and minimize postoperative morbidity compared to open resection. Patients with multiple intra-hepatic tumors are not ideal candidates for resection as this often represents intrahepatic metastasis. Although technically feasible in some patients, multiple hepatic lesion resection must be reviewed on a case by case basis[63,64]. Further, vascular invasion significantly reduces the five year survival rate from around 50% to 10%. Individuals with a MELD score greater than 9 have a high mortality rate after resection and alternative therapies should be considered.
Unfortunately, hepatic resection does not alter the course of underlying cirrhosis. At 2 years, 43% to 65% of patients will have a recurrent tumor and by 5 years post-resection 70% will have recurrent HCC[67,68]. Pre-operative predictors of recurrent free survival include: Child-Pugh class, hepatic function, degree of fibrosis, total serum bilirubin, platelet count, portal hypertension, micro/macroscopic vascular invasion and tumor burden (number and size). A case by case selection for patients with cirrhosis is essential to limit complications and mortality. Operative mortality ranges from 4% to 4.7% for resection with the majority of deaths likely in patients with underlying cirrhosis and large tumor burden. As newer treatment options for HCV are developed, treatment of underlying cirrhosis after resection may alter/delay the development of recurrent HCC.
Liver transplantation offers a potential cure of HCC as it treats the malignancy and the underlying cirrhosis. Given the scarcity of livers available for transplantation, one must carefully select patients to optimize outcomes.
Patients with HCC complicated by cirrhosis and/or portal hypertension should be evaluated for liver transplantation as it carries the lowest rate of tumor recurrence. Traditionally 3 scoring criteria are utilized to determine eligibility [Milan Criteria, University of California San Francisco (UCSF)] and prioritize patients for transplant MELD. The Milan Criteria considers patients eligible for liver transplantation if they present with a single nodule less than 5 cm in diameter or 3 nodules with each less than 3 cm, without evidence of distant metastasis or vascular invasion. With the initial trial showing a 4 year survival rate of 75% and results verified in further studies, organ allocation societies including united network for organ sharing have adopted this criteria[71-73]. Recurrent free survival for patients meeting Milan criteria is 90% with a 4 year overall survival rate of 85%. In contrast patients exceeding criteria parameters have a respective 59% and 50% rate of survival. The UCSF criteria proposed in 2001 expands the eligibility requirements set forth by the Milan criteria to include more patients with HCC. This criteria included individuals with a single tumor less than 6.5 cm or those with 3 nodules less than 4.5 cm (total diameter of no more than 8 cm). Experience with the UCSF criteria has shown similar survival rates compared to the Milan criteria[74,75]. Unfortunately, the paucity of organs available for transplant remains a major obstacle.
Liver allocation is prioritized by the MELD score. All HCC patients have an adjusted MELD score of 22 with increases at each 3 mo interval. Prioritized allocation with MELD score adjustment has increased the number of HCC patients undergoing liver transplantation.
Chemical (ethanol, acetic acid) or thermal ablation [radiofrequency ablation (RFA), microwave, laser, cryoablation] are also used to treat HCC. Historically, percutaneous ethanol injection (PEI) had been used to induce cellular dehydration/necrosis in small HCC tumors. RFA has largely replaced PEI as studies have shown higher rates of complete response with fewer number of treatment sessions[76-78]. RFA is superior to PEI in large and small lesions, although the benefit of using RFA is more pronounced in tumors larger than 2 cm in diameter. Combination RFA and PEI for high risk lesions is an area of ongoing research with promising results.
In cases of early stage HCC where surgical resection or liver transplantation are not feasible, RFA is a minimally invasive approach to local ablation. Therapeutic effects are a result of thermal tumor necrosis, parenchymal and protein destruction. Overall complication rates for RFA are low and are minimized when performed by an experienced physician. Efficacy of RFA is limited by tumor size and location, with a less than fifty percent rate of ablation in tumors larger than 5 cm. RFA is also discouraged in large lesions as the risk of side effects may outweigh benefits. Further, therapy near large vessels may not achieve adequate temperature for coagulative necrosis. Tumors adjacent to intestine or large bile ducts may also preclude RFA.
Rate of recurrence for RFA is higher compared to surgical resection. For large and small tumors, RFA was associated with a significantly lower survival rate compared to surgical resection[85,86]. Thus investigating RFA as a bridge to surgical intervention is logically area of research. Several retrospective studies have shown that pre-transplant RFA delays tumor progression and extends time on the liver transplant list[87-90]. As a major limitation remains the number of organs available for transplant it remains unclear whether the extended time on the liver transplantation list will translate into improved clinical outcomes. Currently guidelines from AASLD support the use of RFA as a bridge to liver transplantation (level II evidence), although the exact role of bridging therapies has not been defined.
Blood supply to HCC tumors are mainly from the hepatic artery. Transarterial chemoembolization (TACE) is the selective occlusion of the blood supply to the tumor with synergistic local distribution of chemotherapy and radioactive substances. The hypervascularity of HCC allows for this targeted therapy, minimizing side effects. The choice of chemotherapeutic agent is not standardized and may include agents such as doxorubicin, cisplatin or epirubicin.
For patients who are not candidates for liver transplantation or resection with tumors too large for local ablation, TACE is effective salvage therapy. Other criteria for treatment include: preserved liver function and no evidence of extrahepatic metastasis or vascular invasion. Approximately 35%-40% of patients will achieve a 25% decrease in tumor size with response rates as high as 60% when surrogate markers for response are utilized[91-93]. A meta-analysis of six randomized controlled trials showed that patients who underwent TACE had a 2-year improved survival rate compared to those who only had supportive therapy. Interestingly, a meta-analysis of nine trials did not show a significant difference in survival based on chemotherapeutic agent used in TACE treatments. Growing literature supports the efficacy of TACE for HCC down-staging and bridging. The first study to use TACE prior to liver transplantation was published in 1997 and showed successful down-staging of tumors greater than 3 cm with a significant improvement in 5-year survival compared to no TACE. More recent studies show that 22% to 70% of patients were successfully downstaged with a 2-year post-transplant survival rate of 81%, and among advanced stage HCC (III/IV) patients a median survival of 20 mo[96-101]. Based on response to therapy, repeat TACE treatments can be scheduled. More intense therapies may be associated with increased risk of acute hepatic decompensation and should be weighed against the potential gains from therapy. Transarterial radioembolization (TARE), a method of delivering internal radiation to the neoplasm using Yttrium 90, represents an alternative to TACE in intermediate stage HCC. This modality of treatment is indicated in patients with portal vein thrombosis where conventional TACE is contraindicated. Survival and response rates for TARE were comparable to TACE while a low side effect profile allows for treatment to be completed in the outpatient setting[103,104].
Novel modalities such as drug-eluting beads-TACE (DEB-TACE) are being investigated in the non-transplant and as neo-adjuvant therapy in patients awaiting transplant. The drug-eluting beads appear to enhance medication delivery and reduce side effects by gradually releasing chemotherapy agents. The PRECISION trial compared non-transplant HCC patients who received DEB-TACE vs TACE. Sub-group analysis revealed a significantly lower hepatic/cardiac toxicity profile in the DEB-TACE group. A small retrospective analysis in transplant patients also showed that DEB-TACE had improved rates of response with minimal adverse effects compared to embolization alone.
Systemic therapies for the management of patients with HCC continue to be researched. Cytologic agents such as tamoxifen, doxorubicin, everolimus and thalidomide have shown marginal success. Targeted molecular therapies such as bevacizumab, brivanib, erlotinib may be alternatives to conventional cytologic agents. To date, sorafenib is the only systemic therapy effective for treating advanced stage HCC. Sorafenib is an oral tyrosine kinase inhibitor with anti-angiogenic activity, and now is the standard of care in treating individuals with advanced stage HCC and Child’s A cirrhosis[107,108]. Patients with minimal tumor related symptoms, vascular invasion and extrahepatic spread are considered ideal for treatment. Clinical experience has shown significant delay in tumor proliferation and angiogenesis with sorafenib therapy. Those with decompensated cirrhosis or those with a less than 3 mo life expectancy should not receive sorafenib. Adverse events include diarrhea, hand foot skin reaction, and fatigue and dose reduction achieves tolerance in most patients.
The Sorafenib HCC Assessment Randomized Protocol was a multi-center double-blinded controlled phase III trial that demonstrated a 31% decrease in risk of death with a median 3 mo delay in radiologic progression of disease in patients prescribed sorafenib. Further, the Global Investigation of Therapeutic Decisions in HCC which included a heterogeneous population of unresectable HCC patients showed that sorafenib was generally well tolerated in the clinical setting. The role of sorafenib in treating early stage HCC and as neo-adjuvant therapy prior to liver transplantation is evolving. In pre-transplant patients, sorafenib combined with TACE may inhibit angiogenesis and induce tumor necrosis. Other targeted molecular therapies beyond sorafenib continue to be researched and may represent second line agents for patients that fail or are unable to tolerate sorafenib.
HCC is a common cause of malignancy world-wide. Emphasis should be placed on surveillance and early diagnosis. Treatment of HCC has changed significantly over the past few decades with curative options such as liver transplantation, hepatic resection and radiofrequency ablation now available. Further, novel therapies such as DEB-TACE or sorafenib will continue to be areas of research. Despite these advances, there remains much to be learned about HCC. Research into effective prevention and factors that may mitigate malignant transformation should be further explored.
P- Reviewer: Colagrande S S- Editor: Ji FF L- Editor: A E- Editor: Liu SQ